MCID: LNG039
MIFTS: 59

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 73
Squamous Cell Lung Carcinoma 29 6
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 50 C3493
SNOMED-CT 68 254634000
UMLS 73 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to adenocarcinoma and breast adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and Class I MHC mediated antigen processing and presentation. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and brain, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.1 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
2 breast adenocarcinoma 31.6 EGFR KRAS PIK3CA TP53
3 adenosquamous carcinoma 31.6 EGFR KRAS TP53
4 small cell carcinoma 31.2 EGFR PTEN TP53
5 squamous cell carcinoma 31.0 BRAF CCAT2 EGFR FGFR2 FGFR3 HRAS
6 lung cancer susceptibility 3 30.6 BRAF CCAT1 EGFR FGFR3 HRAS KRAS
7 small cell cancer of the lung 30.0 CCAT2 EGFR PIK3CA PTEN TP53 TUG1
8 intrahepatic cholangiocarcinoma 29.7 CCAT1 CCAT2 EGFR FGFR2 KRAS TP53
9 glioma 29.5 BRAF CCAT1 CCAT2 EGFR PIK3CA PTEN
10 cholangiocarcinoma 29.3 CCAT2 EGFR FGFR2 HRAS KRAS PIK3CA
11 lung cancer 28.2 BRAF CCAT1 CCAT2 EGFR FGFR2 HRAS
12 spitz nevus 11.4 BRAF HRAS TP53
13 rare adenocarcinoma of the breast 11.4 KRAS PIK3CA TP53
14 hemifacial hyperplasia 11.4 FGFR2 FGFR3
15 apocrine adenoma 11.4 HRAS KRAS PIK3CA
16 prostate squamous cell carcinoma 11.4 HRAS PIK3CA TP53
17 ethmoid sinus cancer 11.4 EGFR HRAS PIK3CA
18 ethmoid sinus adenocarcinoma 11.4 EGFR HRAS PIK3CA
19 breast squamous cell carcinoma 11.4 EGFR PIK3CA TP53
20 hyperplastic polyposis syndrome 11.4 BRAF KRAS TP53
21 brain stem glioma 11.4 BRAF EGFR PIK3CA TP53
22 nasal cavity adenocarcinoma 11.4 HRAS KRAS TP53
23 aggressive digital papillary adenocarcinoma 11.4 HRAS KRAS PIK3CA
24 ovarian serous cystadenocarcinoma 11.4 BRAF HRAS PIK3CA TP53
25 paronychia 11.4 EGFR HRAS KRAS
26 nevus, epidermal 11.4 FGFR3 HRAS KRAS PIK3CA
27 mature teratoma 11.4 BRAF KRAS TP53
28 biliary papillomatosis 11.4 HRAS KRAS TP53
29 lung adenoid cystic carcinoma 11.4 EGFR HRAS KRAS PIK3CA
30 ovarian cancer 1 11.4 HRAS KRAS PIK3CA TP53
31 estrogen-receptor positive breast cancer 11.4 EGFR FGFR2 PIK3CA TP53
32 acneiform dermatitis 11.4 EGFR HRAS KRAS PIK3CA
33 mixed cell type cancer 11.4 HRAS KRAS TP53
34 nevus of ota 11.4 BRAF TP53
35 ovary adenocarcinoma 11.3 HRAS KRAS TP53
36 brain ependymoma 11.3 EGFR TP53
37 pulmonary blastoma 11.3 EGFR KRAS TP53
38 lung benign neoplasm 11.3 EGFR HRAS KRAS TP53
39 skin squamous cell carcinoma 11.3 BRAF HRAS KRAS PIK3CA TP53
40 biliary tract neoplasm 11.3 HRAS KRAS TP53
41 liver angiosarcoma 11.3 HRAS KRAS TP53
42 serous cystadenocarcinoma 11.3 HRAS PIK3CA TP53
43 sigmoid neoplasm 11.3 HRAS KRAS
44 penile cancer 11.3 EGFR HRAS TP53
45 malignant ovarian surface epithelial-stromal neoplasm 11.3 EGFR HRAS KRAS PIK3CA TP53
46 ovary epithelial cancer 11.3 EGFR HRAS KRAS PIK3CA TP53
47 bile duct adenocarcinoma 11.3 HRAS KRAS TP53
48 adenosquamous cell lung carcinoma 11.3 EGFR FGFR3 HRAS KRAS PIK3CA
49 gastrointestinal system benign neoplasm 11.3 HRAS KRAS TP53
50 colorectal adenocarcinoma 11.3 BRAF EGFR HRAS KRAS TP53

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.36 HRAS PIK3CA BRAF EGFR KRAS
2 Decreased viability GR00106-A-0 10.36 KRAS
3 Decreased viability GR00221-A-1 10.36 FGFR3 KRAS HRAS EGFR PIK3CA
4 Decreased viability GR00221-A-2 10.36 FGFR3 KRAS HRAS PIK3CA
5 Decreased viability GR00221-A-3 10.36 FGFR3 HRAS
6 Decreased viability GR00221-A-4 10.36 BRAF EGFR PIK3CA
7 Decreased viability GR00301-A 10.36 KRAS BRAF
8 Decreased viability GR00381-A-1 10.36 BRAF KRAS
9 Decreased viability GR00402-S-2 10.36 FGFR3 HRAS PIK3CA BRAF EGFR KRAS
10 Decreased cell migration GR00055-A-1 9.73 HRAS BRAF EGFR KRAS FGFR3 PIK3CA
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.63 HRAS EGFR FGFR2 FGFR3 PTEN PTPN11
12 Increased cell migration GR00055-A-3 9.02 HRAS BRAF EGFR KRAS PIK3CA

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.22 TP53 PTPN11 BRAF FGFR2 EGFR FGFR3
2 integument MP:0010771 10.22 TP53 PTPN11 BRAF FGFR2 EGFR FGFR3
3 endocrine/exocrine gland MP:0005379 10.2 PTEN TP53 PTPN11 EGFR BRAF FGFR2
4 craniofacial MP:0005382 10.18 TP53 PTPN11 BRAF FGFR2 EGFR FGFR3
5 embryo MP:0005380 10.16 PTEN TP53 PTPN11 EGFR BRAF FGFR2
6 neoplasm MP:0002006 10.16 PTPN11 TP53 BRAF FGFR2 EGFR FGFR3
7 adipose tissue MP:0005375 10.13 PTEN TP53 PTPN11 EGFR BRAF FGFR2
8 hearing/vestibular/ear MP:0005377 10.08 TP53 PTPN11 BRAF FGFR2 EGFR FGFR3
9 muscle MP:0005369 10.08 PTEN TP53 PTPN11 EGFR BRAF FGFR2
10 normal MP:0002873 10.06 PTEN TP53 PTPN11 EGFR BRAF FGFR2
11 limbs/digits/tail MP:0005371 10.05 PTEN TP53 PTPN11 EGFR FGFR2 KRAS
12 liver/biliary system MP:0005370 10.04 PTEN TP53 PTPN11 EGFR BRAF FGFR2
13 no phenotypic analysis MP:0003012 10.03 TP53 PTPN11 FGFR2 EGFR KRAS FGFR3
14 renal/urinary system MP:0005367 9.92 PTEN TP53 BRAF FGFR2 EGFR KRAS
15 pigmentation MP:0001186 9.91 TP53 PTPN11 BRAF FGFR2 EGFR PTEN
16 reproductive system MP:0005389 9.91 PTEN TP53 PTPN11 EGFR BRAF FGFR2
17 respiratory system MP:0005388 9.81 TP53 PTPN11 BRAF FGFR2 EGFR FGFR3
18 skeleton MP:0005390 9.65 TP53 PTPN11 PTEN BRAF FGFR2 EGFR
19 vision/eye MP:0005391 9.28 TP53 PTPN11 BRAF FGFR2 EGFR KRAS

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124
4
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
5
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
6
Nedaplatin Approved, Investigational Phase 4,Phase 3 95734-82-0
7
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
11 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
13 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
17 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
25 tyrosine Nutraceutical Phase 4,Phase 2,Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
27
Cyclophosphamide Approved, Investigational Phase 3,Phase 1 50-18-0, 6055-19-2 2907
28
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
29
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
30
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
31
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
32
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
33
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
34
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
35
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
36
nivolumab Approved Phase 3,Phase 2 946414-94-4
37
Palbociclib Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 571190-30-2 11431660 5005498 5330286
38
Ponatinib Approved, Investigational Phase 2, Phase 3 943319-70-8 24826799
39
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
40
Iniparib Investigational Phase 3 160003-66-7
41
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
42 Talazoparib Investigational Phase 2, Phase 3 1207456-01-6
43
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6
44 Alkylating Agents Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1
47 Etoposide phosphate Phase 3,Phase 2,Phase 1
48 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
49 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
50 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 220)
# Name Status NCT ID Phase Drugs
1 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
2 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
4 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
5 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
6 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
7 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
8 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
9 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
10 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
11 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
12 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
13 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
14 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
15 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
16 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
17 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
18 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
19 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
20 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
21 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
22 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
23 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
24 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
25 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
26 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
27 Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
28 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
29 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC Recruiting NCT03150875 Phase 3 Docetaxel
30 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
31 Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC Recruiting NCT02455843 Phase 3
32 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
33 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
34 Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
35 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
36 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
37 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
38 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
39 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
40 Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer Not yet recruiting NCT03262948 Phase 3 nab-paclitaxel;Paclitaxel;Carboplatin
41 Photodynamic Therapy for the Prevention of Lung Cancer Not yet recruiting NCT03346304 Phase 2, Phase 3
42 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer Not yet recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
43 Ponatinib for Squamous Cell Lung and Head and Neck Cancers Terminated NCT01761747 Phase 2, Phase 3 ponatinib
44 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
45 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
46 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
47 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
48 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
49 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
50 Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Genetic tests related to Lung Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Lung Carcinoma 29

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

41
Lung, T Cells, Brain, Testes, Lymph Node, Bone, Endothelial

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 352)
# Title Authors Year
1
The Positive Relationship Between I^H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. ( 29275316 )
2018
2
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma. ( 29891994 )
2018
3
Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III. ( 29748009 )
2018
4
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. ( 29920955 )
2018
5
Correction: Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. ( 29437123 )
2018
6
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. ( 29394946 )
2018
7
LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. ( 29756998 )
2018
8
Secondary Hypertrophic Osteoarthropathy Associated With Pediatric Primary Lung Squamous Cell Carcinoma. ( 29652703 )
2018
9
Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition. ( 29731224 )
2018
10
Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma. ( 29720381 )
2018
11
TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma. ( 29749538 )
2018
12
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. ( 29384143 )
2018
13
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. ( 29763624 )
2018
14
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. ( 29853661 )
2018
15
Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin. ( 29805594 )
2018
16
17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells. ( 29953987 )
2018
17
Macrophage inducible nitric oxide synthase promotes the initiation of lung squamous cell carcinoma by maintaining circulated inflammation. ( 29844374 )
2018
18
The anti-tumor effect of regorafenib in lung squamous cell carcinoma inA vitro. ( 29944884 )
2018
19
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. ( 29318765 )
2018
20
Identification of a progression-associated long non-coding RNA signature for predicting the prognosis of lung squamous cell carcinoma. ( 29434705 )
2018
21
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. ( 29902295 )
2018
22
Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. ( 29286099 )
2018
23
Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type. ( 29866243 )
2018
24
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. ( 29305708 )
2018
25
Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. ( 29725421 )
2018
26
Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets. ( 29340250 )
2018
27
Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. ( 29673101 )
2018
28
Lung squamous cell carcinoma associated with hypoparathyroidism with sensorineural deafness and renal dysplasia syndrome: a case report. ( 29593425 )
2018
29
CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma. ( 29285191 )
2018
30
m<sup>6</sup>A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. ( 29842885 )
2018
31
Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling. ( 29778566 )
2018
32
A three-microRNA signature for lung squamous cell carcinoma diagnosis in Chinese male patients. ( 29156844 )
2017
33
Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma. ( 28656229 )
2017
34
A case report of tongue metastasis from lung squamous cell carcinoma and literature review: Erratum. ( 29382026 )
2017
35
Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma. ( 28604655 )
2017
36
YAP suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 axis and ROS accumulation. ( 28916653 )
2017
37
Airway Basal Cell Heterogeneity and Lung Squamous Cell Carcinoma. ( 28821543 )
2017
38
A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma. ( 28881596 )
2017
39
Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. ( 29279354 )
2017
40
Oligometastatic Stomach Carcinoma From Lung Squamous Cell Carcinoma Detected by 18F-FDG PET/CT. ( 28719444 )
2017
41
A Case of IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. ( 29279511 )
2017
42
Functional analysis of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in patients with lung squamous cell carcinoma. ( 28693175 )
2017
43
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. ( 28724602 )
2017
44
Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas. ( 29204322 )
2017
45
ALK and ROS1 double-rearranged lung squamous cell carcinoma responding to crizotinib treatment: a case report. ( 28911956 )
2017
46
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. ( 28794006 )
2017
47
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma. ( 28586036 )
2017
48
Klotho expression is correlated to molecules associated with epithelial-mesenchymal transition in lung squamous cell carcinoma. ( 29142604 )
2017
49
Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients. ( 28840006 )
2017
50
[Overexpression of OLC1 in Lung Squamous Cell Carcinoma Tissues is Associated with Poor Prognosis of Patients]. ( 28532543 )
2017

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6
(show top 50) (show all 529)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
20 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
21 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
22 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
23 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
24 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
25 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
26 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
27 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
28 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
29 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic rs121918499 GRCh37 Chromosome 10, 123279562: 123279562
30 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic rs121918499 GRCh38 Chromosome 10, 121520048: 121520048
31 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
32 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
33 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
34 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
35 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
36 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
37 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
38 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
39 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
40 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
43 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
44 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
45 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
46 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
47 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
48 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
49 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh38 Chromosome 7, 140781611: 140781611
50 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403

Cosmic variations for Lung Squamous Cell Carcinoma:

9
(show top 50) (show all 5111)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96301 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522V 2:135200405-135200405 16
2 COSM4987559 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 16
3 COSM6490907 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 16
4 COSM6491476 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 16
5 COSM6491424 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 16
6 COSM6492724 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 16
7 COSM6492589 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 16
8 COSM6492792 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 16
9 COSM95568 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.551G>A p.R184H 16:2002647-2002647 16
10 COSM3717849 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 16
11 COSM6492197 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 16
12 COSM6492124 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 16
13 COSM96300 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36L 19:53571702-53571702 16
14 COSM95561 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 16
15 COSM6492895 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.597G>A p.T199T 3:147395943-147395943 16
16 COSM6492512 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 16
17 COSM6492817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33V 3:147410211-147410211 16
18 COSM6492511 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46A 3:147410250-147410250 16
19 COSM6492818 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 16
20 COSM6492896 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 16
21 COSM6491849 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 16
22 COSM6492224 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 16
23 COSM6491404 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973L 8:76707874-76707874 16
24 COSM6934209 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.899A>G p.H300R 16:72959247-72959247 16
25 COSM6491202 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5661A>G p.K1887K 16:72797021-72797021 16
26 COSM6941511 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.539A>T p.K180M 16:72959607-72959607 16
27 COSM6964178 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1513G>T p.D505Y 16:72958633-72958633 16
28 COSM6938564 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.7158G>A p.M2386I 16:72795524-72795524 16
29 COSM6971408 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6568A>T p.K2190* 16:72796114-72796114 16
30 COSM6946347 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.4628G>A p.R1543H 16:72798054-72798054 16
31 COSM6967898 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1724A>C p.E575A 16:72958422-72958422 16
32 COSM6971764 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1867G>T p.A623S 16:72958279-72958279 16
33 COSM6491691 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6884A>T p.Q2295L 16:72795798-72795798 16
34 COSM6934208 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.2734C>G p.P912A 16:72950951-72950951 16
35 COSM6941055 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1282A>T p.T428S 16:72958864-72958864 16
36 COSM6492881 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.8849G>T p.R2950L 16:72793833-72793833 16
37 COSM973521 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5830G>A p.A1944T 16:72796852-72796852 16
38 COSM6492450 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.708G>T p.K236N 2:144404015-144404015 16
39 COSM6491664 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.515C>T p.T172I 2:144404913-144404913 16
40 COSM6491233 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.2418C>T p.F806F 2:144398769-144398769 16
41 COSM6492147 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.2805G>A p.M935I 2:144398382-144398382 16
42 COSM6491571 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.3074G>C p.R1025T 2:144390022-144390022 16
43 COSM95691 ZCCHC2 lung,NS,carcinoma,squamous cell carcinoma c.3073G>T p.G1025* 18:62575154-62575154 16
44 COSM95554 ZAP70 lung,NS,carcinoma,squamous cell carcinoma c.188G>A p.R63H 2:97724224-97724224 16
45 COSM95552 YWHAG lung,NS,carcinoma,squamous cell carcinoma c.113C>T p.S38L 7:76330208-76330208 16
46 COSM96294 YWHAE lung,NS,carcinoma,squamous cell carcinoma c.660C>T p.I220I 17:1354266-1354266 16
47 COSM6968831 YES1 lung,NS,carcinoma,squamous cell carcinoma c.808T>A p.W270R 18:743332-743332 16
48 COSM6944975 YES1 lung,NS,carcinoma,squamous cell carcinoma c.22G>C p.E8Q 18:756806-756806 16
49 COSM95549 YAP1 lung,NS,carcinoma,squamous cell carcinoma c.485A>G p.Q162R 11:102114307-102114307 16
50 COSM1022110 XPO1 lung,NS,carcinoma,squamous cell carcinoma c.2461C>G p.Q821E 2:61485815-61485815 16

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
2
Show member pathways
13.55 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
3
Show member pathways
13.47 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
4
Show member pathways
13.39 EGFR FGFR2 FGFR3 HRAS KRAS PTEN
5
Show member pathways
13.22 EGFR FGFR2 FGFR3 PIK3CA PTEN PTPN11
6
Show member pathways
13.17 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
7
Show member pathways
13.08 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
8
Show member pathways
13.02 BRAF EGFR HRAS KRAS PIK3CA TP53
9
Show member pathways
13.02 BRAF EGFR HRAS KRAS PIK3CA PTEN
10
Show member pathways
13 BRAF HRAS KRAS PIK3CA PTEN PTPN11
11
Show member pathways
13 BRAF EGFR HRAS KRAS PIK3CA PTEN
12
Show member pathways
12.97 FGFR2 FGFR3 HRAS KRAS PIK3CA PTPN11
13
Show member pathways
12.97 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
14
Show member pathways
12.91 BRAF EGFR FGFR2 HRAS KRAS PIK3CA
15
Show member pathways
12.88 BRAF EGFR HRAS KRAS PTEN
16 12.88 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
17
Show member pathways
12.83 BRAF HRAS KRAS PIK3CA PTEN PTPN11
18
Show member pathways
12.79 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
19
Show member pathways
12.78 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
20
Show member pathways
12.76 EGFR HRAS KRAS PIK3CA PTEN
21
Show member pathways
12.76 BRAF EGFR HRAS KRAS TP53
22
Show member pathways
12.75 BRAF EGFR FGFR2 HRAS KRAS PIK3CA
23 12.73 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
24
Show member pathways
12.71 EGFR HRAS KRAS PIK3CA PTPN11 TP53
25
Show member pathways
12.69 HRAS KRAS PIK3CA PTEN PTPN11
26 12.68 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
27
Show member pathways
12.67 HRAS KRAS PIK3CA PTEN TP53
28
Show member pathways
12.66 BRAF EGFR HRAS KRAS PIK3CA TP53
29
Show member pathways
12.66 BRAF FGFR2 FGFR3 HRAS KRAS PIK3CA
30
Show member pathways
12.66 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
31
Show member pathways
12.62 BRAF HRAS KRAS PIK3CA PTPN11
32 12.61 EGFR FGFR3 HRAS KRAS PIK3CA PTEN
33
Show member pathways
12.59 HRAS KRAS PIK3CA PTEN PTPN11
34
Show member pathways
12.57 BRAF EGFR HRAS KRAS PIK3CA PTPN11
35
Show member pathways
12.56 FGFR2 FGFR3 HRAS KRAS PIK3CA PTPN11
36
Show member pathways
12.52 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
37
Show member pathways
12.51 EGFR HRAS KRAS PIK3CA PTPN11
38
Show member pathways
12.51 BRAF HRAS KRAS PIK3CA PTPN11
39
Show member pathways
12.5 HRAS KRAS PIK3CA PTPN11
40 12.5 HRAS KRAS PIK3CA TP53
41
Show member pathways
12.5 BRAF HRAS KRAS PIK3CA PTEN PTPN11
42
Show member pathways
12.49 FGFR2 FGFR3 PIK3CA PTPN11
43
Show member pathways
12.47 EGFR FGFR2 FGFR3 HRAS
44 12.47 EGFR FGFR2 FGFR3 HRAS
45
Show member pathways
12.44 HRAS KRAS PIK3CA PTEN PTPN11
46
Show member pathways
12.43 HRAS KRAS PIK3CA PTPN11
47
Show member pathways
12.4 EGFR HRAS KRAS PIK3CA
48 12.38 HRAS KRAS PIK3CA TP53
49
Show member pathways
12.35 EGFR FGFR2 FGFR3 HRAS KRAS PTEN
50
Show member pathways
12.34 BRAF HRAS KRAS PTPN11 TP53

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 BRAF EGFR FGFR2 FGFR3 PTEN TP53
2 positive regulation of cell proliferation GO:0008284 9.95 EGFR FGFR2 FGFR3 HRAS KRAS PTEN
3 positive regulation of gene expression GO:0010628 9.93 BRAF HRAS KRAS PTEN TP53
4 leukocyte migration GO:0050900 9.91 HRAS KRAS PIK3CA PTPN11
5 axon guidance GO:0007411 9.89 HRAS KRAS PIK3CA PTPN11
6 positive regulation of MAPK cascade GO:0043410 9.83 EGFR FGFR2 FGFR3 HRAS
7 liver development GO:0001889 9.82 EGFR KRAS PIK3CA
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 BRAF EGFR PIK3CA
9 fibroblast growth factor receptor signaling pathway GO:0008543 9.8 FGFR2 FGFR3 PTPN11
10 Ras protein signal transduction GO:0007265 9.8 HRAS KRAS TP53
11 negative regulation of neuron apoptotic process GO:0043524 9.8 BRAF HRAS KRAS PIK3CA
12 positive regulation of protein kinase B signaling GO:0051897 9.8 EGFR FGFR2 FGFR3 PIK3CA PTPN11
13 MAPK cascade GO:0000165 9.8 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
14 positive regulation of kinase activity GO:0033674 9.79 EGFR FGFR2 FGFR3
15 cellular response to drug GO:0035690 9.78 BRAF EGFR TP53
16 positive regulation of MAP kinase activity GO:0043406 9.76 EGFR HRAS KRAS
17 negative regulation of signal transduction GO:0009968 9.76 BRAF EGFR FGFR2 FGFR3
18 positive regulation of epithelial cell proliferation GO:0050679 9.75 EGFR FGFR2 HRAS
19 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.67 FGFR2 FGFR3 PIK3CA PTPN11
20 regulation of synaptic transmission, GABAergic GO:0032228 9.65 KRAS PTEN
21 organ growth GO:0035265 9.64 FGFR2 PTPN11
22 regulation of multicellular organism growth GO:0040014 9.61 FGFR2 PIK3CA PTPN11
23 positive regulation of phospholipase activity GO:0010518 9.6 FGFR2 FGFR3
24 regulation of axon regeneration GO:0048679 9.57 BRAF PTEN
25 response to isolation stress GO:0035900 9.56 HRAS KRAS
26 ERBB2 signaling pathway GO:0038128 9.56 EGFR HRAS KRAS PIK3CA
27 endochondral bone growth GO:0003416 9.55 FGFR2 FGFR3
28 phosphatidylinositol phosphorylation GO:0046854 9.55 EGFR FGFR2 FGFR3 PIK3CA PTPN11
29 epidermal growth factor receptor signaling pathway GO:0007173 9.35 EGFR HRAS KRAS PIK3CA PTPN11
30 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 BRAF EGFR FGFR2 FGFR3 HRAS PTEN

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.73 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
2 MAP kinase kinase kinase activity GO:0004709 9.62 BRAF EGFR FGFR2 FGFR3
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR2 FGFR3
4 mitogen-activated protein kinase kinase binding GO:0031434 9.46 BRAF EGFR FGFR2 FGFR3
5 insulin receptor substrate binding GO:0043560 9.43 PIK3CA PTPN11
6 fibroblast growth factor-activated receptor activity GO:0005007 9.37 FGFR2 FGFR3
7 1-phosphatidylinositol-3-kinase activity GO:0016303 9.26 FGFR2 FGFR3 PIK3CA PTPN11
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 EGFR FGFR2 FGFR3 PIK3CA PTPN11

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....